JAK2 and systemic lupus erythematosus: As part of the inhibition of cytokine signaling through JAK1 and JAK2 in patients with SLE, the mechanism of action of baricitinib may be mediated partially through the downstream inhibition of autoreactive B cell activation, as manifest by reduction in IgG and autoantibodies including anti-dsDNA.